Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 451–500 of 18616
Michael Ssebugwawo resigned from his positions as Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), Secretary, and Treasurer of SUN (the "Company").
On June 8, 2026, Brady Corporation (the “Company”) announced that Russell R. Shaller will be retiring as the Company’s President and Chief Executive Officer, effective June 8, 2026 (the “Effective Date”).
The Company also announced that, as of June 8, 2026, Vineet Nargolwala has been appointed President and Chief Executive Officer.
As of June 5, 2026, the Company has commenced legal proceedings against its former Chief Financial Officer, Kenneth W. Perry (the "Former CFO"), in the matter of Regenerex Pharma, Inc. v. Kenneth W. Perry , Smith County Chancery Court, Case No. 2026-CV-8813.
appointed Roy Cohen as the Chief Financial Officer, to serve at the discretion of the Board, until his successor is duly appointed and qualified, with such appointment being effective as of June 1, 2026.
On June 9, 2026, Wei Zurui ceased to serve as Chief Financial Officer and a member of the Board of Directors of the Company.
On June 9, 2026, the Board of Directors of the Company appointed Zhao Ling to serve as the Chief Executive Officer and a member of the Board of Directors of the Company.
On June 9, 2026, Chen Yuanhang ceased to serve as Chief Executive Officer of LVPAI GROUP LIMITED
On June 9, 2026, the Board of Directors of the Company appointed Zhang Wenmin to serve as Chief Financial Officer of the Company.
Christopher Marrs would cease serving as President and Chief Executive Officer of the Company as of October 1, 2026.
Mr. Schutt was appointed Chief Executive Officer of the Company effective October 1, 2026.
On June 1, 2026, the Board of Directors (the “Board”) of DENTSPLY SIRONA Inc. (the “Company”) appointed John C. Fortson as the Company’s Executive Vice President & Chief Financial Officer, effective as of July 20, 2026 (the “Effective Date”).
the Board will relieve Mr. Yossi Balucka from his role as Chief Executive Officer of the Company.
On June 8, 2026, Elias J. Sabo informed Compass Group Diversified Holdings LLC (the “Company”) and Compass Diversified Holdings (NYSE: CODI) (the “Trust” and, together with the Company, “CODI”), as well as Compass Group Management LLC (“CGM”) and Sostratus LLC (“Sostratus”), of his decision to retire from his position as the Chief Executive Officer and a director of the Company and as a regular trustee of the Trust, each effective December 31, 2026.
Effective January 1, 2027, Zach Sawtelle will become the Chief Executive Officer of the Company, as well as a regular trustee of the Trust, and Sostratus’ designated appointee to the Board.
On June 5, 2026, Olenox Industries, Inc. (the “Company”) informed Patricia Kaelin, Chief Financial Officer of the Company, of her dismissal from the Company, and the Company received a resignation letter back from her the same day.
the appointment of Daniel Herz as Chief Executive Officer and President of the Company
the appointment of Jeffrey Slotterback as Chief Financial Officer, Treasurer and Secretary of the Company
On June 5, 2026, Jay D. Martin, Chief Financial Officer of Credit Acceptance Corporation (referred to as the “Company,” “Credit Acceptance,” “we,” “our” or “us”) and, as such, the Company’s principal financial officer and principal accounting officer, informed the Company that he has decided to retire as an officer and employee of the Company effective July 27, 2026.
On June 8, 2026, the board of directors of the Company (the “Board”) elected and appointed Joseph Billante to succeed Mr. Martin as the Company’s Chief Financial Officer effective July 27, 2026.
On June 10, 2026, Elizabeth S. Perkins, the Company’s Senior Vice President and Chief Financial Officer, was appointed as, and assumed the additional role of, the Company’s principal accounting officer.
appointment of Mitchell C. Rock as the Company’s Chief Executive Officer
On June 9, 2026, Ketan Seth resigned as Chief Executive Officer and a director of the Company, effective immediately. His resignation was for family reasons and was not due to any disagreement with the Company.
On the same day, the board of directors of the Company appointed David Bauer, the Company’s current Chief Financial Officer, to also serve as the Company’s interim Chief Executive Officer.
On June 4, 2026, the board of directors of Purebase Corporation (the “Company”) appointed Dr. Amy T. Clemens to serve as the Chief Financial Officer of the Company.
On June 4, 2026, Jay Kim notified the Board of Directors (the “Board”) of Reborn Coffee, Inc. (the “Company”) of his resignation as Co-Chief Executive Officer of the Company and the Board accepted the resignation, effective immediately.
Chief Executive Officer Jung Jae Lim, who has served as Co-Chief Executive Officer of the Company since March 2026, has assumed full responsibilities as Chief Executive Officer.
On June 3, 2026, Dzmitry Kastahorau notified AI Era Corp. (the “Company”) of his resignation as Chief Financial Officer of the Company, effective immediately on June 3, 2026.
the Company announced that the Board of Directors of the Company (the “Board”) appointed Ian Ferry as the Company's Executive Vice President, Chief Financial Officer and Treasurer, effective June 9, 2026
Christopher M. Miller, Executive Vice President, Chief Financial Officer, will depart the Company effective June 26, 2026
Mr. Wong will cease serving as principal accounting officer, but will continue to serve as Fastly's Chief Financial Officer.
On June 3, 2026, the Federal Home Loan Bank of New York (“FHLBNY”) appointed Brinda Bhattacharjee, 43, as its Chief Financial Officer (“CFO”), effective immediately.
Effective June 9, 2026, the Company appointed Dr. Kimel as Chief Financial Officer of the Company.
appointed Craig Wichner as the Company’s Chief Executive Officer on June 8, 2026.
The Board of Directors of Quanterix Corporation (the "Company") has appointed Jason Faessler as the Chief Financial Officer and Treasurer of the Company.
On June 7, 2026, Jared Oasheim, the Chief Financial Officer (“CFO”) of CVRx, Inc. (the “Company”), gave notice of his intention to resign from the Company to pursue other professional opportunities.
Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.
Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.
the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed James Sapirstein as the Chief Executive Officer of the Company, effective immediately
On June 2, 2026 the Board appointed Loïc Gautier (“Mr. Gautier”) as Chief Financial Officer of the Company, effective June 2, 2026.
Effective June 5, 2026, Xiangying Meng was appointed Chairman of the Board and Chief Executive Officer of the Company.
Effective June 5, 2026, Guangzhe Su resigned from all positions with the Company, including as Chairman of the Board, Chief Executive Officer and director.
Leah Brown, the Company’s Chief Financial Officer, resumed her previous position as Senior Vice President of Accounting.
Also effective June 8, 2026, Adrian Goldfarb has been appointed Interim Chief Financial Officer.
On June 8, 2026, Satellogic Inc. (the “Company”) and Rick Dunn mutually agreed that Mr. Dunn will step down as the Company’s Chief Financial Officer at the conclusion of a transition period agreed between Mr. Dunn and the Company.
On June 8, 2026, the Board of Directors (the “Board”) of Elite Express Holding Inc. (the “Company”) appointed Ye Hua as the Company’s Chief Financial Officer, effective as of June 8, 2026.
On June 2, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026 (the “Effective Date”).
Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Mira Pharmaceuticals, Inc. (the “Company”).
On June 3, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026
Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Telomir Pharmaceuticals, Inc. (the "Company"). Mr. Weichselbaum’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.